Sorry, you need to enable JavaScript to visit this website.

Dosing and Administration

A single tablet, once a day, with or without food1

Icon of a hand holding a single pill.

The recommended dosage of PEMAZYRE is 13.5 mg orally once daily on a continuous basis

Continue treatment until disease progression or unacceptable toxicity occurs.

Icon of a table setting.

PEMAZYRE can be taken

with or without food

Icon of a single pill.

Do not

crush, chew, split, or dissolve tablets

Icon of a clock.

Instruct patients to take their dose of PEMAZYRE

at approximately the same time every day

Icon of a clock.

Instruct patients to take their dose of PEMAZYRE

at approximately the same time every day

Icon of a single pill.

Do not

crush, chew, split, or dissolve tablets

Icon of a 4-hour timer.

If the patient misses a dose by 4 or more hours or if vomiting occurs,

resume dosing with the next scheduled dose

Dosage modifications for MLNs with FGFR1 rearrangement1

PEMAZYRE is available in 3 strengths to enable dose modifications as needed—13.5 mg, 9 mg, and 4.5 mg

PEMAZYRE®'s dosage modification chart. The dosage modification is as follows: 13.5mg for the starting dose. 9mg for the first dose reduction, 4.5mg for the second dose reduction, and 4.5mg for the third dose reduction.
PEMAZYRE®'s dosage modification chart. The dosage modification is as follows: 13.5mg for the starting dose. 9mg for the first dose reduction, 4.5mg for the second dose reduction, and 4.5mg for the third dose reduction.

*Permanently discontinue PEMAZYRE if the patient is unable to tolerate 4.5 mg once daily for 14 days of each 21-day cycle.

Reduce the dose of PEMAZYRE for adverse reactions

  • Retinal pigment epithelial detachment (RPED): If asymptomatic and stable on serial examination, continue PEMAZYRE. If symptomatic or worsening on serial examination, withhold PEMAZYRE; if asymptomatic and improved on subsequent examination, resume PEMAZYRE at a lower dose. If symptoms persist or no improvement is observed upon examination, consider permanent discontinuation of PEMAZYRE based on clinical status
  • Hyperphosphatemia: If serum phosphate is >7 mg/dL to ≤10 mg/dL, initiate phosphate-lowering therapy and monitor serum phosphate weekly. Withhold PEMAZYRE if levels are not <7 mg/dL within 2 weeks of starting phosphate-lowering therapy, and resume PEMAZYRE at the same dose when phosphate levels are <7 mg/dL for first occurrence. Resume at a lower dose level for subsequent recurrences. If serum phosphate is >10 mg/dL, initiate phosphate-lowering therapy and monitor serum phosphate weekly, withhold PEMAZYRE if levels are not ≤10 mg/dL within 1 week after starting phosphate-lowering therapy, and resume PEMAZYRE at the next lower dose level when phosphate levels are <7 mg/dL. Permanently discontinue PEMAZYRE for recurrence of serum phosphate >10 mg/dL following 2 dose reductions
  • Other adverse reactions: For Grade 3, withhold PEMAZYRE until the adverse reaction resolves to Grade 1 or baseline. Resume PEMAZYRE at the next lower dose if the adverse reaction resolves within 2 weeks, and permanently discontinue PEMAZYRE if the adverse reaction does not resolve within 2 weeks. Permanently discontinue PEMAZYRE for recurrent Grade 3 after 2 dose reductions. For Grade 4, permanently discontinue PEMAZYRE

Avoid concomitant use of strong and moderate CYP3A inhibitors during treatment with PEMAZYRE

  • If concomitant use with a strong or moderate CYP3A inhibitor cannot be avoided, reduce the dose of PEMAZYRE

Avoid concomitant use of strong and moderate CYP3A inducers with PEMAZYRE

The recommended dosage of PEMAZYRE for patients with severe renal impairment (eGFR estimated by MDRD 15 mL/min/1.73 m² to 29 mL/min/1.73 m²) is 9 mg with the schedule designated for MLNs

The recommended dosage of PEMAZYRE for patients with severe hepatic impairment (total bilirubin > 3 × upper limit of normal [ULN] with any AST) is 9 mg with the schedule designated for MLNs

AST, aspartate aminotransferase; CYP, cytochrome P450; eGFR, estimated glomerular filtration rate; FGFR, fibroblast growth factor receptor; MDRD, Modification of Diet in Renal Disease; MLN, myeloid/lymphoid neoplasm.

Reference

  1. PEMAZYRE Prescribing Information. Wilmington, DE: Incyte Corporation.

Indications and Usage

PEMAZYRE® is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.

Important Safety Information

Ocular Toxicity

Retinal Pigment Epithelial Detachment (RPED): PEMAZYRE can cause RPED, which may cause symptoms such as blurred vision, visual floaters, or photopsia. Clinical trials of PEMAZYRE did not conduct routine monitoring including optical coherence tomography (OCT) to detect asymptomatic RPED; therefore, the incidence of asymptomatic RPED with PEMAZYRE is unknown.

Among 635 patients who received a starting dose of PEMAZYRE 13.5 mg across clinical trials, RPED occurred in 11% of patients, including Grade 3-4 RPED in 1.3%. The median time to first onset of RPED was 56 days. RPED led to dose interruption of PEMAZYRE in 3.1% of patients, and dose reduction and permanent discontinuation in 1.3% and in 0.2% of patients, respectively. RPED resolved or improved to Grade 1 levels in 76% of patients who required dosage modification of PEMAZYRE for RPED.

Perform a comprehensive ophthalmological examination including OCT prior to initiation of PEMAZYRE and every 2 months for the first 6 months and every 3 months thereafter during treatment. For onset of visual symptoms, refer patients for ophthalmologic evaluation urgently, with follow-up every 3 weeks until resolution or discontinuation of PEMAZYRE. Modify the dose or permanently discontinue PEMAZYRE as recommended in the prescribing information for PEMAZYRE.

Dry Eye: Among 635 patients who received a starting dose of PEMAZYRE 13.5 mg across clinical trials, dry eye occurred in 31% of patients, including Grade 3-4 in 1.6% of patients. Treat patients with ocular demulcents as needed.

Hyperphosphatemia and Soft Tissue Mineralization

PEMAZYRE can cause hyperphosphatemia leading to soft tissue mineralization, cutaneous calcification, calcinosis, and non-uremic calciphylaxis. Increases in phosphate levels are a pharmacodynamic effect of PEMAZYRE. Among 635 patients who received a starting dose of PEMAZYRE 13.5 mg across clinical trials, hyperphosphatemia was reported in 93% of patients based on laboratory values above the upper limit of normal. The median time to onset of hyperphosphatemia was 8 days (range 1-169). Phosphate lowering therapy was required in 33% of patients receiving PEMAZYRE.

Monitor for hyperphosphatemia and initiate a low phosphate diet when serum phosphate level is >5.5 mg/dL. For serum phosphate levels >7 mg/dL, initiate phosphate lowering therapy and withhold, reduce the dose, or permanently discontinue PEMAZYRE based on duration and severity of hyperphosphatemia as recommended in the prescribing information.

Embryo-Fetal Toxicity

Based on findings in an animal study and its mechanism of action, PEMAZYRE can cause fetal harm when administered to a pregnant woman. Oral administration of pemigatinib to pregnant rats during the period of organogenesis caused fetal malformations, fetal growth retardation, and embryo-fetal death at maternal exposures lower than the human exposure based on area under the curve (AUC) at the clinical dose of 13.5 mg.

Advise pregnant women of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment with PEMAZYRE and for 1 week after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with PEMAZYRE and for 1 week after the last dose.

Adverse Reactions: Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Serious adverse reactions occurred in 53% of patients receiving PEMAZYRE at all dosages (n=34). Serious adverse reactions in > 5% of patients included acute kidney injury. Fatal adverse reactions occurred in 9% of patients who received PEMAZYRE, including acute kidney injury, multiple organ dysfunction syndrome, and malignant neoplasm progression, occurring in one patient each.

Permanent discontinuation due to an adverse reaction occurred in 12% of patients who received PEMAZYRE at all dosages. Adverse reactions requiring permanent discontinuation included cardiac failure, multiple organ dysfunction syndrome, blood alkaline phosphatase increase, and calciphylaxis. In patients who started treatment on the recommended dosage (n = 20), adverse reactions requiring dosage interruption of PEMAZYRE occurred in 80% of patients. Adverse reactions which required dosage interruption in > 2 patients treated at the recommended dosage included nail toxicities (20%) and hyperphosphatemia (15%).

Dose reductions of PEMAZYRE due to an adverse reaction occurred in 80% of patients who started treatment on the recommended dosage. Adverse reactions requiring dose reductions occurring in > 2 patients were nail toxicities (20%), hyperphosphatemia (20%), and alopecia (15%).

Clinically relevant adverse reactions occurring in ≤10% of patients included fractures (2.1%). In all patients treated with pemigatinib, 0.5% experienced pathologic fractures (which included patients with and without cholangiocarcinoma [N = 635]). Soft tissue mineralization, including cutaneous calcification, calcinosis, and non-uremic calciphylaxis associated with hyperphosphatemia were observed with PEMAZYRE treatment.

Within the first 21-day cycle of PEMAZYRE dosing, serum creatinine increased (mean increase of 0.2 mg/dL) and reached steady state by Day 8, and then decreased during the 7 days off therapy. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed.

The most common (≥ 20%) adverse reactions were hyperphosphatemia (74%), nail toxicity (62%), alopecia (59%), stomatitis (53%), diarrhea (50%), dry eye (50%), fatigue (44%), rash (35%), abdominal pain (35%), anemia (35%), constipation (32%), dry mouth (32%), epistaxis (29%), retinal pigment epithelial detachment (26%), extremity pain (26%), decreased appetite (24%), dry skin (24%), dyspepsia (24%), back pain (24%), nausea (21%), blurred vision (21%), peripheral edema (21%), and dizziness (21%).

Drug Interactions

Avoid concomitant use of strong and moderate CYP3A inhibitors with PEMAZYRE. Reduce the dose of PEMAZYRE if concomitant use with a strong or moderate CYP3A inhibitor cannot be avoided. Avoid concomitant use of strong and moderate CYP3A inducers with PEMAZYRE.

Special Populations

Advise lactating women not to breastfeed during treatment with PEMAZYRE and for 1 week after the last dose.

Reduce the recommended dose of PEMAZYRE for patients with severe renal impairment as described in the prescribing information.

Reduce the recommended dose of PEMAZYRE for patients with severe hepatic impairment as described in the prescribing information.